welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
not yet recruiting

A Phase 3 Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids, in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)

key information

study id #: NCT04632940

condition: Duchenne Muscular Dystrophy

status: not yet recruiting

purpose:

To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids administered every two weeks in ambulatory subjects with Duchenne muscular dystrophy (age 6 to <12 years).

intervention: Pamrevlumab, Placebo

mechanism of action: Fibrosis preventor to support muscle

results: https://clinicaltrials.gov/ct2/show/results/NCT04632940?view=results

last updated: December 01, 2020